R. Landgraf is the lead author and declares the following potential conflicts of interest: Advisory Boards: Lilly Deutschland, Novo Nordisk Pharma; has received lecture fees from: AstraZeneca, Berlin Chemie, Lilly Deutschland, Novo Nordisk Pharma. Other activities: Representative of the Executive Board of the German Diabetes Foundation, Steering committee for the development and updating of the National Treatment Guidelines/Nationalen Versorgungsleitlinien Diabetes. J. Aberle is a member of advisory boards and has received lecture fees from: Astra Zeneca, Berlin-Chemie, Boehringer-Ingelheim, Eli Lilly & Co, Novo Nordisk, Roche Diabetes Care. Institutional research funding: Astra Zeneca. A. L. Birkenfeld is member of Advisory Boards and has received lecture fees from: Amgen, Astra Zeneca, Boehringer-Ingelheim, Eli Lilly & Co, Merck Sharp & Dohme, Novo Nordisk, Sanofi. Institutional research funding: Boehringer Ingelheim. B. Gallwitz declares the following potential conflicts of interest over the last 3 years: Advisory Boards/Consultancy: Amgen, AstraZeneca, Bayer Vital, Boehringer Ingelheim, Eli Lilly & Co., Merck Sharp & Dohme, Mylan, Novo Nordisk; Lecturing activities: Amgen, AstraZeneca, Bristol Myers Squibb, Boehringer-Ingelheim, Eli Lilly & Co., Merck Sharp & Dohme, Novartis, Novo Nordisk, Sanofi; Company shares: none. M. Kellerer is a co-author and declares the following potential conflicts of interest: Research support: GlaxoSmithKline, AstraZeneca; Consultancy: Abbott, AstraZeneca, Boehringer Ingelheim, Lilly, MSD, Novo Nordisk; Lecturing activities: AstraZeneca, Boehringer Ingelheim, Lilly, MSD, Novo Nordisk, Novartis, Janssen-Cilag, Sanofi. H. Klein declares the following potential conflicts of interest: Advisory Board: AstraZeneca, Janssen Cilag, Boehringer Ingelheim; Lecture fees: Berlin-Chemie. D. Müller-Wieland declares the following potential conflicts of interest: Member of the Advisory Board and lecture fees in the last 3 years from the following companies: Amgen, MSD, AstraZeneca, Novartis, Boehringer Ingelheim, Lilly, Novo Nordisk, Roche Diabetes Care, Sanofi. M. A. Nauck declares the following potential conflicts of interest: Member of the Advisory Board: Berlin Chemie, Boehringer Ingelheim, Fractyl, Eli Lilly & Co., GlaxoSmithKline, MSD, Novo Nordisk, Intarcia Therapeutics; Consultancy fees: AstraZeneca, Berlin Chemie, Boehringer Ingelheim, Eli Lilly & Co., GlaxoSmithKline, Intarcia Therapeutics, MSD, Novo Nordisk; Fees: AstraZeneca, Berlin Chemie, Boehringer Ingelheim, Eli Lilly & Co., Medscape, MSD, Novo Nordisk, Research Support: AstraZeneca, Eli Lilly & Co., GSK, MSD, Novo Nordisk, Novartis. H.-M. Reuter declares that he has served on Advisory Boards for Lilly Germany, Berlin-Chemie, MSD, Novo Nordisk, BMS and AstraZeneca over the past 3 years and has received lecture fees from Lilly, MSD, Berlin-Chemie, BMS, Amgen, Bayer, Boehringer Ingelheim, Sanofi and AstraZeneca. E. Siegel declares that he had no economic or personal conflicts of interest concerning this manuscript.